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Cardiovascular biomaterials (CB) dominate the category of biomaterials based on the demand and investments in this field.
This review article classifies the CB into three major classes, namely, metals, polymers, and biological materials and collates the
information about the CB. Blood compatibility is one of the major criteria which limit the use of biomaterials for cardiovascular
application. Several key players are associated with blood compatibility and they are discussed in this paper. To enhance the
compatibility of the CB, several surface modification strategies were in use currently. Some recent applications of surface
modification technology on the materials for cardiovascular devices were also discussed for better understanding. Finally, the
current trend of the CB, endothelization of the cardiac implants and utilization of induced human pluripotent stem cells (ihPSCs),
is also presented in this review. The field of CB is growing constantly and many new investigators and researchers are developing
interest in this domain. This review will serve as a one stop arrangement to quickly grasp the basic research in the field of CB.
1. Introduction
Last ten decades have shown tremendous growth in the field
of material science and it is very synonymous to say that
some materials have been used successfully to replace, assist,
and repair some parts of the body and its functions. These
materials widely called biomaterial. Numerous definitions
for biomaterial by various scientists add some explored or
unidentified scope to the definition. Some of the definitions
of biomaterials are as follows. To beginwith,Williams around
1987 stated “a nonviable material used in a medical device,
intended to interact with biological systems” [1]. It was
in 1999, Williams defined biocompatibility as “ability of a
material to perform with an appropriate host response in
a specific situation” [2]. This definition drastically changed
the bird-view of biomaterials, until then that successful
biomaterials played largely inert roles in the body. By the
way, with respect to the above definition, that biomaterial
not only provides some function, but also induces some bio-
logical responses. By accommodating the above and various
considerations, a wide and distinct definition of biomaterials
was made recently in Williams dictionary of biomaterials
(2008) as follows: “ability of a biomaterial to perform its
desired function with respect to a medical therapy, without
eliciting any undesirable local or systemic effects in the
recipient or beneficiary of that therapy, but generating the
most appropriate beneficial cellular or tissue response to
that specific situation, and optimizing the clinically relevant
performance of that therapy” [3].
According to the recent reports of MarketsandMarkets, it
has been forecasted that by 2017 the estimated global market
for biomaterials will be 88.4 billion US$ with a compound
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annual growth rate (CAGR) of 15%. To add further, it has
been estimated that Asian market is to grow at highest
CAGR of 21.5% because of large number of people with
disorders necessitating biomaterial-based medical products
[4]. Nowadays, biomaterials are commonly used in various
medical devices and systems: synthetic skin, drug delivery
systems, tissue cultures, hybrid organs, synthetic blood ves-
sels, artificial hearts, cardiac pacemakers, screws, plates, wires
and pins for bone treatments, total artificial joint implants,
skull reconstruction, and dental and maxillofacial applica-
tions [5–7]. Among various applications, the application of
biomaterials in cardiovascular system is most significant.
The use of cardiovascular biomaterials is projected to be
predominant category of the biomaterials market in 2014,
with a worth of about $20.7 billion [4].
The use of cardiovascular biomaterials (CB) is subjected
to its blood compatibility and its integration with the sur-
rounding environment where it is implanted [8]. Whenever,
CB is used, two important considerations should be weighed
equally; namely, (1) physical and mechanical features such
as strength and deformation, fatigue and creep, friction and
wear resistance, flow resistance and pressure drop, and other
characteristics to be engineered must be considered and (2)
biocompatibility or compatibility refers tomaterial and tissue
interactions are also to be considered. These characteristics
have to be tested and appraised in an array of in vivo
and in vitro experiments [9]. The first aspect mentioned
is almost predetermined depending on the material chosen
and its inherent properties. However, the second aspect
biocompatibility is of immense interest for every cardiac
implant material chosen and it decides the patency of the
same. In the next subtitle, biocompatibility of cardiovascular
biomaterials is discussed briefly before we move into the
classification.
2. Biocompatibility of
Cardiovascular Biomaterials
Cardiovascular biomaterials are used in two modes, namely,
temporary and permanent [10]. Based upon mode of use,
cardiovascular devices can be classified as temporary internal,
temporary external, and permanent internal devices [11].
Testing of compatibility of cardiovascular devices largely
depends upon the mode of use. All CB comes with contact
with blood and this duration of contact further determines
the testing parameters. Contact duration may be limited (less
than 24 h), prolonged (>24 h to 30 days), and permanent
(>30 days). Blood compatibility is to be evaluated for all
blood contacting devices irrespective of the contact dura-
tion. According to ISO-10993, thrombogenicity, hemolysis,
and immunology (complement activation) testing has to be
performed for these devices [12, 13].
One of the leading causes of cardiac biomaterial failure
is the initiation of thrombosis formation by the blood con-
tacting devices [14]. The mechanism underlying thrombus
formation is discussed briefly for understanding the reason
behind the cardiac device failure. Adsorption of proteins on
the surface of implanted cardiac biomaterial through intrinsic
pathway or through the release of tissue factor from the
damaged cells at the site of injury (extrinsic pathway) is the
initial event leading to thrombosis. The intrinsic pathway
(Figure 1) is independent of injury and the adsorbed surface
proteins form a complex comprising collagen, highmolecular
weight kininogen (HMWK), prekalikrein, and factor XII.
Further, this complex got cleaved by contact activation
and activates various immune responses like kinin system,
coagulation, fibrinolytic, and complement system. Formation
of clot due to intrinsic pathway system consists of series of
conversion of inactive precursors to active form. To start
with, activated factor XII activates factor XI which thereby
activates factor IX and activated factor IX in turn activates
factor X. Upon activation of factor X, it results in the cleavage
of prothrombin to thrombin in presence of other supporting
cofactors. Activated thrombin converts fibrinogen to fibrin
which eventually gets stabilized as a red thrombus or clot.
A damage to blood vessel endothelium releases tissue factor,
collagen, and von Willebrand (vWF) which activates the
extrinsic pathway. Tissue factors act as cofactor to activate
factor X. There is also a possibility for factor VII to activate
factor IXwhich in turn activate factorX. Except for factorVII,
all factors of extrinsic pathway are similar to intrinsic pathway
leading to the formation of thrombus [15, 16].
Hemolysis may result in impairment of oxygen carrying
capacity of red blood cells (RBC). Hemolysis occurs when the
RBC comes in contact with the material or its degradation
products formed due to the shear stress generated because
of relative motion between blood and the material surface.
Moreover, to ascertain the various complement activation
pathways immunology testing should be performed. ISO-
10993 recommends direct contact in vitro C3a and SC5b-9
fragment activation using established testing methods such
as an ELISA test [12, 13].
In addition to this, some toxic effects may also occur
which is considered to be the components of biocompatibility
and care should be taken to evaluate this depending upon
the cardiac device. An ability to damage the system by means
of chemicals is called toxicity. In higher organisms, toxicity
may produce local and systemic effects. In local toxicity, the
adverse effects emerge only in the affected areas, whereas in
systematic toxicity the effects occur even far away from the
distance of the application of the implant. Components of
toxicity include cytotoxicity, genotoxicity, mutagenicity, and
carcinogenicity. Cytotoxicity refers to the damage that occurs
to the individual cells, that is, cell death due to necrosis or
apoptosis. Genotoxicity refers to the alteration of the base
pair sequence of the genomic DNA. The same genotoxicity
when they are carried to the next generation through genes
is known as mutagenicity. The alterations of the base pair
sometimes lead to the generation of the malignant tumors
referred as carcinogenicity [12, 13].
3. Classification of
Cardiovascular Biomaterials
Cardiovascular application of biomaterials (Figure 2)
includes metals and their alloys, polymers, and some
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Figure 1: Blood clotting cascade: involvement of various clotting factors associated with intrinsic and extrinsic pathway.
biological materials [17, 18]. In this subtitle, a brief discussion
of these cardiovascular biomaterials for various applications
will be highlighted.
3.1. Metals and Alloys. Metals have been used for more than
a century in biomedical field [19]. The use of metals in
cardiovascular applications includes heart valves, endovascu-
lar stents, and stent-graft combinations [20]. In majority of
cardiovascular applications stainless steel, cobalt chromium
(CoCr) alloys and titanium (Ti) alloys are widely used [19].
The basic properties of these common metallic CB are listed
down under Table 1. One of the important applications of
the CB is stents. Stents can be typically classified into three
types based on their function andphysical characters, namely,
bare metal stents (BMS), drug-eluting stent (DES), and
bioabsorbable stents. Metals and alloys utilized under these
categories were discussed briefly to have a basic understand-
ing of applications of metals as CB.
In the beginning, stainless steel used for implants con-
tains vanadium, but it has been replaced with the advent of
18% Cr and 8% Ni alloy making it stronger for applications.
Soon, addition ofmolybdenum (Mo) and reduction of carbon
(C) made it corrosion resistant (316 L) and suitable for blood
Table 1: Relative differences between the three commonly used
metallic alloys as cardiovascular biomaterials.
Properties Stainless steel Co-Cr alloys Ti-alloys
Stiffness Best Better Good
Strength Better Good Best
Corrosion resistance Good Better Best
Blood compatibility Good Better Best
contacting devices like stent. Stainless steel is still the gold
standard material for stent application in order to provide
mechanical support to diseased arteries [21]. Further stainless
steel is also widely used in heart valves, especially in making
struts to support leaflets to avoid corrosion and provide
mechanical strength to the valves.
Recently cobalt (Co) based alloys have gained entry for
production of stents, although Co-based alloys were used
in medicine since 1937. The use of Co-based alloys is highly
preferred in coronary stent manufacturing because coronary
interventionist demands for thinner struts which can be eas-
ily achieved by using the Co-alloys. since it has more strength
compared with 316 L. Further, properties like nonferromag-
netic and denser than stainless steel make driver cobalt alloy
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Figure 2: Classification of cardiovascular biomaterial.
a feasible companion for making coronary stents. MP35N or
cobalt-nickel-chromium-molybdenum (CoNiCrMo) alloys
with a nickel content of 35% are used for cardiovascular
pacing leads, stylets, and catheters. A new arrival cobalt-
chromium-tungsten-nickel (CoCrWNi) alloy, also known as
L-605, is used for making heart valves [22].
Titanium-based alloys (Ti-alloys) have wide acceptance
and usage since 1970. The most commonly used Ti-alloys
are commercially pure titanium (CP-Ti) and 5Ti-6Al-4V
(titanium-aluminium-vanadium). One of the remarkable
features of titanium is light weight. Density of Ti is only
4.5 g/cm3 compared to 7.9 g/cm3 for 316 stainless steel and
8.3 g/cm3 for cast cobalt-chromium-molybdenum (CoCrMo)
alloys [23]. Moreover, Ti-alloys are known for their excellent
tensile strength and pitting corrosion resistance suitable for
cardiovascular applications. Another interesting feature of
titanium alloys is shape memory effect possessed by the
nickel-titanium (nitinol) alloys widely utilized for producing
self-expanding memory stents [24, 25]. Although BMS have
excellent mechanical characteristics, they failed because of
serious limitations such as stent thrombosis which requires
prolonged antiplatelet therapy and mismatch of the stent to
the vessel size. Moreover the metallic stents impair the vessel
geometry and obstruct side branches.
In order to rectify the complications present in BMS,
drug-eluting stents (DES) was developed [26]. The DES were
further classified into polymer free stents and metallic stents
with polymer carrier to hold and release the drug. Drug-
eluting stents basically consist of three parts: stent platform,
coating, and drug. Some of the examples for polymer free
DES are Amazon Pax (MINVASYS) using Amazonia CroCo
(L605) cobalt chromium (Co-Cr) stent with Paclitaxel as
an antiproliferative agent and abluminal coating have been
utilized as the carrier of the drug. BioFreedom (Biosensors
Inc.) using stainless steel as base with modified ablumi-
nal coating as carrier surface for the antiproliferative drug
Biolimus A9. Optima (CID S.r.I.) using 316 L stainless steel
stent as base for the drug Tacrolimus and utilizing integrated
turbostratic carbofilm as the drug carrier. VESTA sync (MIV
Therapeutics) using GenX stainless steel (316 L) as base
utilizing microporous hydroxyapatite coating as carrier for
the drug Sirolimus. YUKON choice (Translumina) used 316 L
stainless steel as base for the drugs Sirolimus in combination
with Probucol [27].
Another version of DES contains biosorbable polymers
as a carrier matrix for drugs. Cypher, Taxus, and Endeavour
are the three basic type of bioabsorbable DES. Cypher (J&J,
Cordis) uses a 316 L stainless steel coated with polyethylene
vinyl acetate (PEVA) and poly-butyl methacrylate (PBMA)
for carrying the drug Sirolimus. Taxus (Boston Scientific)
utilizes 316 L stainless steel stents coated with translute
Styrene Isoprene Butadiene (SIBS) copolymer for carrying
Paclitaxel which elutes over a period of about 90 days [28].
Endeavour (Medtronic) uses a cobalt chrome driver stent for
carrying zotarolimus with phosphorylcholine as drug carrier
[29]. Further some recent advances in the development of
bioabsorbable DES resulted in the production of various new
stent systems which includes BioMatrix employing S-Stent
(316 L) stainless steel as base with polylactic acid surface for
carrying the antiproliferative drug Biolimus. ELIXIR-DES
program (Elixir Medical Corp) consisting both polyester and
polylactide coated stents for carrying the drug novolimus
with cobalt-chromium (Co-Cr) as base. JACTAX (Boston
Scientific Corp.) utilized D-lactic polylactic acid (DLPLA)
coated (316 L) stainless steel stents for carrying Paclitaxel.
NEVO (Cordis Corporation, Johnson& Johnson) used cobalt
chromium (Co-Cr) stent coated with polylactic-co-glycolic
acid (PLGA) for carrying the drug Sirolimus [27]. Though
DES is considered as a breakthrough in the development of
stents; they are still associated with subacute and late throm-
bosis. Further, the polymer used as a vehicle for drug delivery
may induce vessel irritation, endothelial dysfunction, vessel
hypersensitivity, and chronic inflammation at the stent site.
Later they developed bioabsorbable stents to overcome
the above-said problems of DES. Bioabsorbable stents stay for
a limited period and promote healing of the blood vessel.The
main purpose of the stent is to assist the arterial remodeling
and this may take 6–12 months. Hence for a perfect cardio-
vascular application like stents, a wide varied biodegradable
alloys have been experimented with a reasonable degradation
life of 12–24 months [30–33]. This may overcome the need of
unnecessary medication and also avoid late stent thrombosis.
However, material for biodegradable stents is expected to
meet some basic demands as it should be biocompatible and
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also its degradation products of the material must also be
biocompatible. Finally, it should be able to stay in the place
for several months before its complete bioabsorption and
also its radial force of the resultant stent must be enough
for scaffolding effect during the arterial remodeling period
[30]. Based on these requirements, two metallic elements
including iron and magnesium have been explored for this
application [21]. Magnesium alloy stent is the first metallic
bioabsorbable stent implanted in humans. Clinical evaluation
conducted by Heublein et al. demonstrated higher degrada-
tion rates forMg alloy from 60 to 90 days.Moreover, the stent
was well integrated with both endothelial and smoothmuscle
cells indicating its overall biocompatibility [34].
3.2. Polymers. Polymers are the high molecular weight
molecule made up of a small repeating unit called monomer.
Polymers are widely utilized as implant material for car-
diovascular application. Tailor made properties of polymers
and better biocompatibility makes them an ideal choice
when compared with metallic biomaterials [35]. The uses of
polymers in cardiovascular application ranges from vascular
grafts to stents, prosthetic heart valves, catheters, heart
assist devices, hemodialyser, and so forth [35, 36]. In this
section, various commonly used polymers for cardiovascular
application are discussed (Table 2).
3.2.1. Polyamides (PA). PA is considered the first engineering
thermoplastic invented in search of a “super polyester” fiber
with molecular weights greater than 10,000. It is commonly
called Nylon [37]. Application of polyamides includes trans-
parent tubing’s for cardiovascular applications, hemodialysis
membranes, and also production of percutaneous translumi-
nal coronary angioplasty (PTCA) catheters [35].
3.2.2. Polyolefin. Polyolefins are the family of polymers
consisting of a repeating unit of olefin or alkene in their
polymeric chain. Polyethylene and polypropylene are the
two important polymers of polyolefin have a wide range
of medical application because of its better biocompatibility
and chemical resistance [38]. In cardiovascular arena, both
low-density polyethylene and high-density polyethylene are
utilized in making tubing’s and housings for blood supply.
They are also utilized in production of blood bags to store
blood. Polypropylene is used for making heart valve struc-
tures [17, 35].
3.2.3. Polyesters. Polyesters are the family of polymers with
ester functional groups. However, the term polyester was
synonymously used for polyethylene-terephthalate (PET).
Commercialization of PET was popular using the name
Dacron. Synthesis can be done in many forms, but it
is typically used as knitted or woven fabric for vascular
grafts. Woven PET has smaller pores which reduces blood
leakage and better efficiency as vascular grafts compared
with the knitted one. PET grafts are also available with a
protein coating (collagen or albumin) for reducing blood
loss and better biocompatibility [39]. PET vascular grafts
with endothelial cells have been searched as a means for
improving patency rates [40].Moreover, polyesters are widely
preferred material for the manufacturing of bioabsorbable
stents. Poly-L-lactic acids (PLLA), polyglycolic acid (PGA),
and poly(D, L-lactide/glycolide) copolymer (PDLA) are some
of the commonly used bioabsorbable polymers [27]. The
Igaki-Tamai stent constructed frompoly-L-lactic acid (PLLA)
is the first absorbable stent implanted in humans. The
clinical studies showed low complication rates for stent
thrombosis [41]. The BVS everolimus eluting is another type
of bioabsorbable stent coated with poly-D, L-lactide having
metallic base has been using to carry the antiproliferative
drug everolimus. The clinical records expressed lack of stent
thrombosis and ensure total vascular function restoration
[42, 43].
3.2.4. Polytetrafluoroethylene. Polytetrafluoroethylene
(PTFE) is synthetic fluorocarbon polymer with wide array of
applications including biomedical industry. The most
common commercial name of PTFE is Teflon by Dupont Co.
Common applications of PTFE in cardiovascular engi-
neering include vascular grafts and heart valves. PTFE
sutures are used in the repair of mitral valve for myxomatous
disease and also in surgery for prolapse of the anterior or
posterior leaflets of mitral valves. PTFE is particularly used
in implantable prosthetic heart valve rings. It has been
successfully used as vascular grafts when the devices are
implanted in high-flow, large-diameter arteries such as the
aorta. Problem occurs when it is implanted below aortic
bifurcations and another form of PTFE called elongated-
PTFE (e-PTFE) was explored. Expanded PTFE is formed
by compression of PTFE in the presence of career medium
and finally extruding the mixture. Extrudate formed by this
process is then heated to near its glass transition temperature
and stretched to obtain microscopically porous PTFE
known as e-PTFE. This form of PTFE was indicated for
use in smaller arteries with lower flow rates promoting low
thrombogenicity, lower rates of restenosis and hemostasis,
less calcification, and biochemically inert properties
[44–47].
3.2.5. Polyurethanes. Polyurethane is a polymer formed by
repeating units of urethane monomer. It is formed by the
reaction between isocyanates with a polyol. Polyurethane
backbone contains average two or more functional groups
derived from the isocyanates and polyols. Polyurethane is
widely used in cardiovascular application because of its
good physiochemical and mechanical properties. Moreover,
polyurethane is highly biocompatible which allows unre-
stricted usage in blood contacting devices. It has high shear
strength, elasticity, and transparency. Moreover, the surface
of polyurethane has good resistance for microbes and the
thrombosis formation by PU is almost similar to the versatile
cardiovascular biomaterial like PTFE. Conventionally, seg-
mented polyurethanes (SPUs) have been used for various car-
diovascular applications such as valve structures, pacemaker
leads and ventricular assisting device [48]. Further SPUs can
also be tailored to render biodegradable systems for the tissue
engineering of vascular grafts and heart valves [49, 50].
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Table 2: Properties of polymers utilized as cardiovascular biomaterials.
Properties Polyamides Polyolefin Polyester Polytetrafluoroethylene Polyurethanes
Strength Medium Good Good High Better
Hardness Medium High High High Medium
Rigidity Medium High High High Medium
Blood compatibility Good Better Moderate Low Good
Table 3: Characteristics of biological materials used as cardiovascu-
lar biomaterials.
Properties Allograft Xenograft
Strength and durability Moderate Moderate
Blood compatibility Best Better
Blood flow dynamics Better Better
Corrosion resistance Moderate Moderate
3.3. Biological Materials. Metallic and polymeric materials
serve as a better replacement in repair and replacement of
cardiac tissues, but they fail in functional comparison with
biological tissues. Sources of biological tissues range from
human (allograft) to xenografts. Currently there are three
types of bioprosthetic valves available commercially: allograft
or homograft valves, porcine valves, and bovine pericar-
dial valves [51]. Homografts are the intact human valves
received from donors and cryopreserved as entire aortic or
pulmonary roots. During implantation, it is further modified
and adjusted to the size and shape of the recipient [52, 53].
Human donor is limited and xenograft tissues from bovine,
porcine, and equine are explored. Pericardium isolated from
porcine and bovine is used for making the bioprosthetic
valve and it varies slightly depending upon the source.
Collagen content is higher from bovine origin compared
with porcine. Both porcine and bovine valve have displayed
similar hemodynamics; however, bovine pericardial valves
show less obstruction compared to porcine valve [54, 55].
Porcine xenograft valve composed of aortic valve from
pig directly preserved in low-concentration glutaraldehyde
solution. Porcine valves are suited for old patients and they
do not require the anticoagulant regimen as necessitated
by the mechanical valves. Calcification and degradation of
valves are the common problems associated with bovine or
porcine replacements. To overcome these issues, both types
of the tissues are treated with some other chemical agents
in order to minimize their tendency to calcify over the
duration of implantation and thereby improve their longevity.
The use of these natural biomaterials as bioprosthetic valves
and vascular grafts has typically required some chemical or
physical pretreatment aimed to preserve and also increase
the resistance of the material against degradation, thereby
promoting better compatibility, and reduced immunogenic-
ity of the materials [56, 57]. The summary of few important
properties of allograft and xenograft are listed in Table 3.
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surface 
modification
methods
Physical immobilization 
of biological material
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Modifications using 
energy possessing 
substances
Biofunctionalization
Figure 3: Cardiovascular biomaterials surface modification meth-
ods.
4. Surface Modification of
Cardiovascular Biomaterials
One of the major problems associated with cardiac bioma-
terial used for blood contacting devices is the compatibility
of the materials with the blood. To circumvent the above,
various strategies were adopted to modify the surface in
order to improve the compatibility of the material. These
modifications techniques may be broadly classified into three
major classes; namely, physical immobilization of biological
material, chemical modification, and modification of mate-
rials using energy possessing substances like plasma, ion
implantation, and so forth were highlighted in the coming
subsections (Figure 3).
4.1. Physical Immobilization of Biological Material. Physical
immobilization of biological material is a technique utilizes
any biological substance as a simple coating material without
changing the structure of either. Activation and adhesion
ability of the adhered biological material on the surface
dictate the anticoagulation property of the implant. Most
commonly used biological materials that are the proteins of
human origin like heparin, fibronectin, collagen, vitronectin,
and so forth have been found to improve the adhesion
behavior of endothelial cells. Heparinization is one of the
commonly used biological materials for modifying the sur-
face of cardiovascular implants. Several methods have been
used to immobilize heparin on different CB like 316 L SS,
ePTFE, PET, and PU [58]. Concentration of heparin used
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on the implant surface has different effects on the blood
and vascular cells, including endothelial cells (ECs) [59]
and smooth muscle cells (SMCs) [60]. Even some direct
thrombin inhibitors like hirudin and some of its derivatives
like bivalirudin have shown to inhibit the active site of
thrombin and thereby promote blood compatibility [61, 62].
Immobilization of cell-adhesive oligopeptide by covalent
combination on the material surface has found to bind
EC selectively [63]. Immobilization of other anticoagulant
molecules like thrombomodulin (TM) and NO has also
shown improved results. Coimmobilization of TM along-
with urokinase and endothelial protein C receptor has been
investigated by a group [64]. Utilization of NO as an
immobilizing material resulted in the modulation of blood
vessel tone, inhibition of platelet activation, and leucocyte
adhesion and SMC hyperplasia [65]. Several trails involving
the regulation of inflammatory system or complementary
system by using some key players like apyrase [66], CD47
[67], and soluble complement receptor 1 [68] are under
scrutiny.
4.2. Chemical Modifications. Chemical modifications intro-
duce new molecules on the material surface through cou-
pling, grafting, and coating. Diamond like carbonwas used to
coat the artificial heart valves (AHV) [69], ventricular assist
devices (VAD), TiN coating for VAD, and Ti-O in metal
stents [70]. SiC coating for cardiovascular implants resulted
in decrease in platelet adhesion and also less inflammatory
reactions. Diamond like carbon has similar advantages as
SiC and also additionally it provides higher hardness and
smoothness, lower frictional coefficient, chemical inertness,
biostability, and also good blood compatibility making it
an elegant choice for the applications on vascular stents,
AHVs and VADs [71]. Another important chemical modifi-
cation of cardiovascular implants is the use of polyethylene
oxide (PEO) (–CH
2
–CH
2
–O)n and the related molecule
polyethylene glycol (PEG) with hydrophilic long chain (HO–
[CH
2
–CH
2
–O]n–H). Anticoagulation properties of PEO are
dependent on the length of the chain structure and it has
been observed when the repeating unit is over 100 PEO
displayed excellent blood compatibility [72]. Similarly PEG
introduced surface presents excellent blood compatibility
by providing adhesion resistance to small biomolecules like
fibrinogen and cells such as platelets and leukocytes [73]. An
interesting case to mention that is 2-methacryloyloxyethyl
phosphorylcholine (MPC) polymer that was developed two
decades ago is well known for its blood compatibility. It has
been shown that this polymer surface could inhibit platelet
adhesion and minimize the protein adsorption significantly
resulting in wide-spread usage in cardiovascular devices like
dialysis, heart pumps, or VADs [74].
4.3. Modifications Using Energy-Possessing Substances. This
subsection delineates the various energy modification pro-
cesses utilized for cardiovascular implants surface modifi-
cation. Several modes of energy carrier modification are
available. These modes alter the surface of the implant and
also facilitate the addition of coatings to improve the blood
compatibility. Plasma surface modification is one of the
widely utilized techniques to improve blood compatibility
of cardiovascular implants. Air plasma modified segmented
polyurethane holds good for vascular graft application [75].
PET films grafted with acrylic acid was modified using
oxygen plasma before immobilizing with heparin was found
to improve the blood compatibility [76] and also with
collagen to facilitate the growth of smooth muscle cells
[77]. Another important mode of modification is using UV-
exposure. PTFE and PET exposed to UV-irradiation have
been found to facilitate the endothelial and smooth muscle
cell adhesion favorably compared with the unexposed poly-
mers [78]. Similarly laser treatments have also been found
to be exquisite tool to improve the blood compatibility by
providing antithrombogenic surface [79]. Microwave treat-
ment has also conjoined this race and it has been efficient in
producing blood compatible surface on some polymers used
for cardiovascular implants [80]. Ion implantation utilizes
precisely controlled ion species and doses to modify the
surface. Recent investigations implied that ion implanta-
tion can improve the wettability and anticoagulant nature
of polypropylene and polystyrene and thereby promoting
endothelial cell adhesion [81, 82].
5. Biofunctionalization of
Cardiovascular Biomaterials
Endothelium is the layer which surrounds the entire vas-
culature ranging from heart to minute capillaries. A vast
amount of research is instituted to make endothelial surface
on the cardiovascular implants to mimic the natural environ-
ment for better biocompatibility. Endothelial cells are end-
differentiated cells which are not capable of cell dividing and
expansion [83]. Several strategies were employed to promote
anticoagulant or endothelial promoted surface modification
by impregnating the surface with active molecules or vas-
cular cells seeding but due to cost and time involved in
this process outweighed this technology. With the advent
of endothelial progenitor cells (EPC) in 1997, rapid self-
endothelization developed extensively paving the way for
various novel methods for in vivo endothelization on the
surface of cardiovascular implants especially vascular grafts
and stents [84]. EPCs are the relatively small population
of CD34+ circulating mononuclear cells in the circulatory
system available as two forms, namely, early EPC and late
EPC. Based on these two forms, EPC have been exploited in
two different ways: one way is to construct and immobilize
the early EPCs at the site of injury which will secrete
angiogenic cytokines whichwill flourish the resident ECs and
the late EPCs. Another way is to construct the surface with
late EPCswhich in turn promotes neoangiogenesis and repair
the damaged site by their native ability to proliferate at high
rate [85, 86]. As previously stated several active molecules
such as vascular endothelial growth factor (VEGF), stromal
derived factor-1 (SDF-1), nerve growth factor (NGF), and
granulocyte-colony stimulating factor (G-CSF) were utilized
to induce neovascularization and repair the injury [87]. A
recent study utilizing NGF-bound vascular grafts showed
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significant immobilization of EPC and a similar preparation
using SDF-1/heparin found to recruit both EPCs and smooth
muscle progenitor cells tackling the two important issues,
namely, endothelization and remodeling of blood vessels
[88, 89]. EPC capture technology is the way through which
circulating EPC is captured by using anti-CD34+that was
impregnated on the surface of stents. Genous R-Stent is
the first medical device utilizing this technology [90] and
various clinical investigations evaluated this device compre-
hensively. One of the studies postulated that this EPC capture
technology was feasible and safe for primary percutaneous
coronary intervention for STEMI without the incidence
of late stent restenosis [91]. In another independent trial,
coronary stenting with the Genous resulted in good clinical
outcomes and low incidences of repeat revascularization and
stent thrombosis [92]. However, some recent evaluation came
in contrast to the above findings, where they reported higher
risk of restenosis while using Genous compared to drug-
eluting stents [93]. To add further, Genous stent used in
a population of elderly patients resulted in a significantly
higher target vessel failure rates compared with younger
patients. Moreover, target lesion revascularization rates were
higher with increasing age and there was no difference in
stent thrombosis [94]. Another worthy research to mention
is the use of exponential enrichment technology in which
DNA-aptamers with a high affinity to EPCs were identified.
These EPC specific molecules are grafted on the surface of
polymer disk [95], stents [96], and Ti-implants [97] found
to attach EPCs to the aptamer-coated implants.This selective
adhesion of EPCs promoted endothelial wound healing and
also decreased the neointimal hyperplasia to a certain extent.
Recent researches utilize various cell sources for treat-
ment of cardiovascular diseases. Human embryonic stem
cells (h-ESC), mesenchymal stem cells, endothelial progeni-
tor cells, and induced human pluripotent stem cells (ihPSCs)
are some of the cell sources explored for treatment of cardio-
vascular diseases.Themost versatile ihPSCs are induced from
human somatic cells like fibroblast by transfecting with stem
cell associated genes which then exhibit the characteristics
of h-ESCs. Human-iPSCs are preferred for cardiomyocytes
differentiation used for autologous cardiomyocyte transplan-
tation therapy since they provide a better alternative to
human embryonic stem cells (hESCs) derived cardiomy-
ocytes (hESC-CMs) for two reasons. The first reason is that
ihPSC-CMs overcome the political and ethical problems of
damaging the human embryos; and secondly it helps to
achieve a considerable quantity of patient specific cardiomy-
ocytes that could be derived from ihPSCs, thus allowing the
use of autologous cardiomyocytes for transplantation [98].
Recently concluded researches explored cardiomyocytes dif-
ferentiated from ihPSC for long QT syndrome. They isolated
patient-specific cells through skin biopsies, reprogramming
their cells into iPSCs and then differentiating those iPSCs
into cardiac cells. They were successful in treating both long
QT syndrome of types 1 and 2 using these differentiated
cardiomyocytes [99, 100]. Further iPSCs act as a source
material to generate cardiac patch or tissue through cell sheet
technique. Tulloch et al. produced engineered heart tissues
(EHT) from hESC and ihPSC by using a collagen I-based
method and a commercially available system from FlexCell
[101]. Moreover, several groups had shown that iPSCs can be
differentiated in to endothelial and vascular smooth muscle
cells which highlight the potential of these cells for vascular
generation and understanding the mechanism of diseases
such as hypertension, coronary heart disease, and diabetic
cardiomyopathy [102–106].
6. Conclusion
Cardiovascular biomaterials were projected to be predomi-
nant category of the biomaterialsmarket in 2014, with aworth
of about $20.7 billion. Major problem associated with CB is
the blood compatibility and various standards have evolved in
evaluation of biocompatibility of CB.This ensures the quality
of biomaterials used in the cardiovascular applications. CB
falls mainly into three categories, namely, metals, polymers,
and biological materials. Properties of these materials limit
their use in various applications. Polymers have emerged as a
versatile choice for various cardiovascular applications. How-
ever, the problem of blood compatibility is still a major issue
and several surface modifications are adopted to circumvent
this and to develop biocompatible CB.
The field of cardiovascular biomaterials have shown a
growth in the past two decades, but it still lacks more basic
experiments and clinical data that have to be generated
extensively by researchers to augment this area. To list, still
there is a need to develop materials that mimic the properties
of the natural cardiac tissues and this can be done by pro-
ducing composite materials that exhibit the property of both
natural and synthetic materials. Further some novel surface
modification strategies should be evolved to develop better
biocompatible cardiac biomaterials. This can be achieved
by doing research in the field of endothelization and also
utilizing nanotechnology as a tool to modify the CB surfaces.
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